Li, J., Luo, J., Dou, Z., Hou, M. (2026). Acquired resistance to first-line osimertinib is heterogeneous in EGFR-mutant advanced non-small cell lung cancer. Scientific Reports. https://doi.org/10.1038/s41598-026-59570-z